Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Preston Mason

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|April 27, 2021
Kinetics of generic tacrolimus in heart transplantation: A cautionary noteZachary J Il'Giovine, J Bradley Williams, R Preston Mason, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 11, 2022
Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smokingMichael Miller, Deepak L Bhatt, Ph Gabriel Steg, et al.
BMJ Open|December 16, 2020
Double-blind RCT of fish oil supplementation in pregnancy and lactation to improve the metabolic health in children of mothers with overweight or obesity during pregnancy: study protocolVidit V Satokar, Wayne S Cutfield, José G B Derraik, et al.
Journal of the American College of Cardiology|March 26, 2024
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent EthylMichael Szarek, Deepak L Bhatt, Michael Miller, et al.
Circulation|June 28, 2022
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker SubstudyPaul M Ridker, Nader Rifai, Jean MacFadyen, et al.
Journal of the American Heart Association|February 19, 2025
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized TrialRahul Aggarwal, Deepak L Bhatt, Ph Gabriel Steg, et al.
The American Journal of Clinical Nutrition|February 13, 2023
Fish oil supplementation during pregnancy and postpartum in mothers with overweight and obesity to improve body composition and metabolic health during infancy: A double-blind randomized controlled trialVidit V Satokar, José G B Derraik, Matire Harwood, et al.
Thrombosis Research|August 24, 2010
Novel astaxanthin prodrug (CDX-085) attenuates thrombosis in a mouse modelSanjoy K Khan, Tadeusz Malinski, R Preston Mason, et al.
Molecular Genetics and Metabolism|July 5, 2011
Alterations in membrane caveolae and BKCa channel activity in skin fibroblasts in Smith-Lemli-Opitz syndromeGongyi Ren, Robert F Jacob, Yuri Kaulin, et al.
Circulation|October 28, 2021
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENALArjun Majithia, Deepak L Bhatt, Allon N Friedman, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|April 27, 2021
Kinetics of generic tacrolimus in heart transplantation: A cautionary noteZachary J Il'Giovine, J Bradley Williams, R Preston Mason, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 11, 2022
Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smokingMichael Miller, Deepak L Bhatt, Ph Gabriel Steg, et al.
BMJ Open|December 16, 2020
Double-blind RCT of fish oil supplementation in pregnancy and lactation to improve the metabolic health in children of mothers with overweight or obesity during pregnancy: study protocolVidit V Satokar, Wayne S Cutfield, José G B Derraik, et al.
Journal of the American College of Cardiology|March 26, 2024
Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent EthylMichael Szarek, Deepak L Bhatt, Michael Miller, et al.
Circulation|June 28, 2022
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker SubstudyPaul M Ridker, Nader Rifai, Jean MacFadyen, et al.
Journal of the American Heart Association|February 19, 2025
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized TrialRahul Aggarwal, Deepak L Bhatt, Ph Gabriel Steg, et al.
The American Journal of Clinical Nutrition|February 13, 2023
Fish oil supplementation during pregnancy and postpartum in mothers with overweight and obesity to improve body composition and metabolic health during infancy: A double-blind randomized controlled trialVidit V Satokar, José G B Derraik, Matire Harwood, et al.
Thrombosis Research|August 24, 2010
Novel astaxanthin prodrug (CDX-085) attenuates thrombosis in a mouse modelSanjoy K Khan, Tadeusz Malinski, R Preston Mason, et al.
Molecular Genetics and Metabolism|July 5, 2011
Alterations in membrane caveolae and BKCa channel activity in skin fibroblasts in Smith-Lemli-Opitz syndromeGongyi Ren, Robert F Jacob, Yuri Kaulin, et al.
Circulation|October 28, 2021
Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENALArjun Majithia, Deepak L Bhatt, Allon N Friedman, et al.
Pageof 10